Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Leadership transition completed: Mani Mohindru appointed permanent CEO after serving as interim CEO.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Leadership transition completed: Mani Mohindru appointed permanent CEO after serving as interim CEO
- New CFO Josh Muntner effective April 6, with $475,000 salary and 40% discretionary bonus
- Muntner received 486,650 options at $1.58, vesting over four years
- New COO Ajay Aggarwal effective April 27, with $490,000 salary and 40% discretionary bonus
- Mohindru compensation includes $655,000 salary, $100,000 bonus, 55% discretionary bonus, and 800,000 options total
Item 8.01 · Other Events
- Dr. Mohindru appointed President and CEO, marking a change in Cardiff Oncology’s top executive leadership
- Mr. Muntner appointed Chief Financial Officer, adding new leadership over financial reporting and capital management
- Dr. Aggarwal appointed Chief Operating Officer, signaling an expanded operational leadership structure
- Press release furnished as Exhibit 99.1 for appointment details and transition context
Item EX-99.1 · Exhibit EX-99.1
- Leadership transition formalized with Mani Mohindru named President and CEO after serving as Interim CEO
- Josh Muntner appointed CFO effective April 6, adding biopharma financing and capital-markets experience
- Ajay Aggarwal appointed COO effective April 27, strengthening clinical-development and operational execution
- Muntner received options for 486,650 shares at $1.58 exercise price, vesting over four years
- Appointments target execution of onvansertib’s Phase 2 first-line RAS-mutated metastatic colorectal cancer program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.